Swedish Orphan Biovitrum AB (publ) (Sobi) and Arthrosi Therapeutics, Inc. (Arthrosi) announced the completion of the acquisition of Arthrosi by Sobi. Upon completion of the transaction, Sobi has ...
STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by ...
New research indicates that a drug commonly prescribed for gout may also lower the risk of heart attack and stroke when taken at an appropriate dose. Researchers from the UK, Sweden and Italy analyzed ...
Acute calcific periarthritis (ACP) is defined as periarticular inflammation associated with intra-articular deposits of hydroxyapatite and other basic calcium phosphate crystals. Patients with ACP ...
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An ...
Asymptomatic hyperuricemia Acute/intermittent gout Advanced gout (or what used to be called chronic tophaceous gout). The rate of progression from asymptomatic hyperuricemia to advanced gout varies ...
Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...
The European Alliance of Associations for Rheumatology - recommends that serum urate should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout. But despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results